Dr Jim Whittle, presenting: Selumetinib скачать в хорошем качестве

Dr Jim Whittle, presenting: Selumetinib

The Children's Tumour Foundation held the hybrid NF Community Information Day on Saturday 20 August 2022. This event brought together researchers, clinicians and NF patients and families, to learn more about the support services and treatment options in place to help manage their condition. Dr Jim Whittle is a medical oncologist specialising in neuro-oncology and early phase clinical trials at the Peter MacCallum Cancer Centre. He has a special interest in new therapies to treat plexiform neurofibromas as well as brain tumours associated with neurofibromatosis and improving health related quality of life outcomes for patients. His clinical training was completed at Royal Melbourne Hospital and Peter MacCallum Cancer Centre, followed by a PhD and postdoctoral research (2015–2021) at the WEHI in the Visvader / Lindeman Laboratory. In 2021 Jim was appointed joint laboratory head with Dr Sarah Best and Saskia Freytag in the Personalised Oncology Division at WEHI as part of the establishment of the Brain Cancer Centre. PRESENTING: Selumetinib Dr Whittle provideS details on what Selumetinib is, how it works and the side effects of treatment delving into his experiences in leading the Melbourne arm of the KOMET clinical trial investigating the effectiveness of Selumetinib in adults with NF1-related inoperable plexiform neurofibromas.